Literature DB >> 32107534

Burden of Candidemia in the United States, 2017.

Sharon V Tsay1, Yi Mu2, Sabrina Williams1, Erin Epson3, Joelle Nadle3, Wendy M Bamberg4, Devra M Barter4, Helen L Johnston4, Monica M Farley5,6, Sasha Harb7, Stepy Thomas5,7, Lindsay A Bonner8, Lee H Harrison9, Rosemary Hollick9, Kaytlynn Marceaux9, Rajal K Mody10, Brittany Pattee10, Sarah Shrum Davis11, Erin C Phipps11,12, Brenda L Tesini13,14, Anita B Gellert14, Alexia Y Zhang15, William Schaffner16, Sherry Hillis16, Danielle Ndi17, Caroline R Graber17, Brendan R Jackson1, Tom Chiller1, Shelley Magill2, Snigdha Vallabhaneni1.   

Abstract

BACKGROUND: Candidemia is a common healthcare-associated bloodstream infection with high morbidity and mortality. There are no current estimates of candidemia burden in the United States (US).
METHODS: In 2017, the Centers for Disease Control and Prevention conducted active population-based surveillance for candidemia through the Emerging Infections Program in 45 counties in 9 states encompassing approximately 17 million persons (5% of the national population). Laboratories serving the catchment area population reported all blood cultures with Candida, and a standard case definition was applied to identify cases that occurred in surveillance area residents. Burden of cases and mortality were estimated by extrapolating surveillance area cases to national numbers using 2017 national census data.
RESULTS: We identified 1226 candidemia cases across 9 surveillance sites in 2017. Based on this, we estimated that 22 660 (95% confidence interval [CI], 20 210-25 110) cases of candidemia occurred in the US in 2017. Overall estimated incidence was 7.0 cases per 100 000 persons, with highest rates in adults aged ≥ 65 years (20.1/100 000), males (7.9/100 000), and those of black race (12.3/100 000). An estimated 3380 (95% CI, 1318-5442) deaths occurred within 7 days of a positive Candida blood culture, and 5628 (95% CI, 2465-8791) deaths occurred during the hospitalization with candidemia.
CONCLUSIONS: Our analysis highlights the substantial burden of candidemia in the US. Because candidemia is only one form of invasive candidiasis, the true burden of invasive infections due to Candida is higher. Ongoing surveillance can support future burden estimates and help assess the impact of prevention interventions. Published by Oxford University Press for the Infectious Diseases Society of America 2020.

Entities:  

Keywords:  zzm321990 Candidazzm321990 ; candidemia; communicable diseases; healthcare-associated infections

Year:  2020        PMID: 32107534     DOI: 10.1093/cid/ciaa193

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  21 in total

Review 1.  Minority report: the intestinal mycobiota in systemic infections.

Authors:  Thierry Rolling; Tobias M Hohl; Bing Zhai
Journal:  Curr Opin Microbiol       Date:  2020-06-27       Impact factor: 7.934

2.  Low Sensitivity of International Classification of Diseases, Tenth Revision Coding for Culture-Confirmed Candidemia Cases in an Active Surveillance System: United States, 2019-2020.

Authors:  Kaitlin Benedict; Jeremy A W Gold; Emily N Jenkins; Jeremy Roland; Devra Barter; Christopher A Czaja; Helen Johnston; Paula Clogher; Monica M Farley; Andrew Revis; Lee H Harrison; Laura Tourdot; Sarah Shrum Davis; Erin C Phipps; Christina B Felsen; Brenda L Tesini; Gabriela Escutia; Rebecca Pierce; Alexia Zhang; William Schaffner; Meghan Lyman
Journal:  Open Forum Infect Dis       Date:  2022-09-07       Impact factor: 4.423

3.  Recognition of Diagnostic Gaps for Laboratory Diagnosis of Fungal Diseases: Expert Opinion from the Fungal Diagnostics Laboratories Consortium (FDLC).

Authors:  Sean X Zhang; N Esther Babady; Kimberly E Hanson; Amanda T Harrington; Paige M K Larkin; Sixto M Leal; Paul M Luethy; Isabella W Martin; Preeti Pancholi; Gary W Procop; Stefan Riedel; Seyedmojtaba Seyedmousavi; Kaede V Sullivan; Thomas J Walsh; Shawn R Lockhart
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

Review 4.  Prevalence of biofilms in Candida spp. bloodstream infections: A meta-analysis.

Authors:  María Belén Atiencia-Carrera; Fausto Sebastián Cabezas-Mera; Eduardo Tejera; António Machado
Journal:  PLoS One       Date:  2022-02-03       Impact factor: 3.240

5.  Increasing morbidity and mortality of candidemia over one decade in a Swiss university hospital.

Authors:  Julien Battistolo; Emmanouil Glampedakis; Lauro Damonti; Julien Poissy; Bruno Grandbastien; Laetitia Kalbermatter; Jean-Luc Pagani; Philippe Eggimann; Pierre-Yves Bochud; Thierry Calandra; Oscar Marchetti; Frederic Lamoth
Journal:  Mycoses       Date:  2021-10-19       Impact factor: 4.931

Review 6.  What 'Omics can tell us about antifungal adaptation.

Authors:  Gabriela Fior Ribeiro; Eszter Denes; Helen Heaney; Delma S Childers
Journal:  FEMS Yeast Res       Date:  2022-01-11       Impact factor: 2.923

7.  Combining Colistin and Fluconazole Synergistically Increases Fungal Membrane Permeability and Antifungal Cidality.

Authors:  Maayan Bibi; Sarah Murphy; Raphael I Benhamou; Alex Rosenberg; Adi Ulman; Tihana Bicanic; Micha Fridman; Judith Berman
Journal:  ACS Infect Dis       Date:  2021-01-20       Impact factor: 5.084

8.  Antifungal Activity of Minocycline and Azoles Against Fluconazole-Resistant Candida Species.

Authors:  Jingwen Tan; Shaojie Jiang; Lihua Tan; Haiyan Shi; Lianjuan Yang; Yi Sun; Xiuli Wang
Journal:  Front Microbiol       Date:  2021-05-13       Impact factor: 5.640

9.  Antifungal susceptibility profile of Candida clinical isolates from 22 hospitals of São Paulo State, Brazil.

Authors:  D K B Rodrigues; L X Bonfietti; R A Garcia; M R Araujo; J S Rodrigues; V M F Gimenes; M S C Melhem
Journal:  Braz J Med Biol Res       Date:  2021-06-14       Impact factor: 2.590

10.  A seven-year surveillance study of the epidemiology, antifungal susceptibility, risk factors and mortality of candidaemia among paediatric and adult inpatients in a tertiary teaching hospital in China.

Authors:  Zhangrui Zeng; Yinhuan Ding; Gang Tian; Kui Yang; Jian Deng; Guangrong Li; Jinbo Liu
Journal:  Antimicrob Resist Infect Control       Date:  2020-08-14       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.